Association of a Proposed New Staging System for Folliculotropic Mycosis Fungoides With Prognostic Variables in a US Cohort
Authors:
Open Access
- 1 February 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 157 (2) , 157-165
Abstract
Folliculotropic mycosis fungoides (FMF) was recognized as a distinct entity and distinguished from conventional mycosis fungoides (CMF) by its clinicopathologic features and purportedly worse prognosis.1-8 Differing survival data for FMF have been reported. In 2002, the first retrospective cohort study of patients with FMF4 reported a poor prognosis when compared with stage-matched patch- or plaque-stage CMF, with 5- and 10-year disease-specific survival (DSS) rates of 68% and 26%, respectively, and 5- and 10-year overall survival rates of 64% and 14%, respectively. In 2008, a US study5 also reported poor survival, with 10- and 15-year overall survival rates of 82% and 41%, respectively. However, later non-US studies described better survival,9-14 including a few reporting overall survival as favorable as 94%11 to 100%.10,12 It has been hypothesized that such discrepancies partially stem from using different FMF definitions and therefore that studies have analyzed different cohorts of patients. In particular, it has been suggested that studies reporting a poorer prognosis included mostly patients with advanced-stage disease, whereas others demonstrating a good prognosis included mostly patients with early-stage disease. Therefore, a new FMF-specific staging system, which divides patients between early and advanced cutaneous stages, has been proposed.15 This system, currently lacking full validation, is considered potentially better associated with survival in FMF compared with the tumor-node-metastasis-blood (TNMB) system for CMF. Thus, we sought to test its utility in estimating survival in our institutional cohort of patients with FMF. In addition, although the implicit assumption behind using cutaneous stage as the parameter is that stage is best associated with survival, we wanted to test this assumption in our cohort by performing Cox proportional hazards regression modeling to examine multiple variables associated with overall survival and DSS in the entire cohort.Keywords
This publication has 18 references indexed in Scilit:
- Juvenile mycosis fungoides: Cutaneous T-cell lymphoma with frequent follicular involvementJournal of the American Academy of Dermatology, 2014
- Clinical and Histopathological Features of Folliculotropic Mycosis Fungoides: A Norwegian Patient SeriesActa Dermato-Venereologica, 2013
- Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging ProposalJournal of Clinical Oncology, 2010
- Folliculotropic Mycosis FungoidesArchives of Dermatology, 2010
- Folliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 casesJournal of the American Academy of Dermatology, 2010
- Folliculotropic Mycosis FungoidesArchives of Dermatology, 2008
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary SyndromeArchives of Dermatology, 2003
- Follicular Mycosis Fungoides, a Distinct Disease Entity With or Without Associated Follicular MucinosisArchives of Dermatology, 2002
- Follicular MucinosisArchives of Dermatology, 2002